210 related articles for article (PubMed ID: 34532458)
1. Co-mutations of epidermal growth factor receptor and BRAF in Chinese non-small cell lung cancer patients.
Peng P; Lv G; Hu J; Wang K; Lv J; Guo G
Ann Transl Med; 2021 Aug; 9(16):1321. PubMed ID: 34532458
[TBL] [Abstract][Full Text] [Related]
2. Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI.
Klempner SJ; Bazhenova LA; Braiteh FS; Nikolinakos PG; Gowen K; Cervantes CM; Chmielecki J; Greenbowe JR; Ross JS; Stephens PJ; Miller VA; Ali SM; Ou SH
Lung Cancer; 2015 Sep; 89(3):357-9. PubMed ID: 26187428
[TBL] [Abstract][Full Text] [Related]
3. Concurrent Driver Gene Mutations as Negative Predictive Factors in Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer.
Chen M; Xu Y; Zhao J; Zhong W; Zhang L; Bi Y; Wang M
EBioMedicine; 2019 Apr; 42():304-310. PubMed ID: 30878600
[TBL] [Abstract][Full Text] [Related]
4. Mutational profiling of non-small-cell lung cancer patients resistant to first-generation EGFR tyrosine kinase inhibitors using next generation sequencing.
Jin Y; Shao Y; Shi X; Lou G; Zhang Y; Wu X; Tong X; Yu X
Oncotarget; 2016 Sep; 7(38):61755-61763. PubMed ID: 27528220
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer.
Chen HJ; Mok TS; Chen ZH; Guo AL; Zhang XC; Su J; Wu YL
Pathol Oncol Res; 2009 Dec; 15(4):651-8. PubMed ID: 19381876
[TBL] [Abstract][Full Text] [Related]
6. Plasma
Wang X; Liu Y; Meng Z; Wu Y; Wang S; Jin G; Qin Y; Wang F; Wang J; Zhou H; Su X; Fu X; Wang X; Shi X; Wen Z; Jia X; Qin Q; Gao Y; Guo W; Lu S
Ann Transl Med; 2021 Apr; 9(8):635. PubMed ID: 33987333
[TBL] [Abstract][Full Text] [Related]
7. Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients.
Ko R; Kenmotsu H; Serizawa M; Koh Y; Wakuda K; Ono A; Taira T; Naito T; Murakami H; Isaka M; Endo M; Nakajima T; Ohde Y; Yamamoto N; Takahashi K; Takahashi T
BMC Cancer; 2016 Nov; 16(1):864. PubMed ID: 27821131
[TBL] [Abstract][Full Text] [Related]
8. Next-generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancer.
Zhang Y; Xiong L; Xie F; Zheng X; Li Y; Zhu L; Sun J
Cancer Med; 2021 Jul; 10(14):4697-4709. PubMed ID: 34173341
[TBL] [Abstract][Full Text] [Related]
9. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
Shea M; Costa DB; Rangachari D
Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
[TBL] [Abstract][Full Text] [Related]
10. Genetic alterations in epidermal growth factor receptor-tyrosine kinase inhibitor-naïve non-small cell lung carcinoma.
Yamaura T; Muto S; Mine H; Takagi H; Watanabe M; Ozaki Y; Inoue T; Fukuhara M; Okabe N; Matsumura Y; Hasegawa T; Osugi J; Hoshino M; Higuchi M; Shio Y; Suzuki H
Oncol Lett; 2020 Jun; 19(6):4169-4176. PubMed ID: 32391110
[TBL] [Abstract][Full Text] [Related]
11. Coexistence of EGFR, KRAS, BRAF, and PIK3CA Mutations and ALK Rearrangement in a Comprehensive Cohort of 326 Consecutive Spanish Nonsquamous NSCLC Patients.
Martín Martorell P; Huerta M; Compañ Quilis A; Abellán R; Seda E; Blesa S; Chaves FJ; Dualde Beltrán D; Roselló Keränen S; Franco J; Insa A
Clin Lung Cancer; 2017 Nov; 18(6):e395-e402. PubMed ID: 28550959
[TBL] [Abstract][Full Text] [Related]
12. A lung adenocarcinoma patient with co-mutations of MET and EGFR exon20 insertion responded to crizotinib.
Chen Y; Jiang B; He Y; Zhang C; Zhou W; Fang C; Gu D; Zhang M; Ji M; Shi J; Yang X
BMC Med Genomics; 2022 Jun; 15(1):141. PubMed ID: 35739536
[TBL] [Abstract][Full Text] [Related]
13. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
Gelatti ACZ; Drilon A; Santini FC
Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
[TBL] [Abstract][Full Text] [Related]
14. Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC).
Labbé C; Cabanero M; Korpanty GJ; Tomasini P; Doherty MK; Mascaux C; Jao K; Pitcher B; Wang R; Pintilie M; Leighl NB; Feld R; Liu G; Bradbury PA; Kamel-Reid S; Tsao MS; Shepherd FA
Lung Cancer; 2017 Sep; 111():23-29. PubMed ID: 28838393
[TBL] [Abstract][Full Text] [Related]
15. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.
Byeon S; Lee B; Park WY; Choi YL; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
Clin Lung Cancer; 2020 May; 21(3):e182-e190. PubMed ID: 31839532
[TBL] [Abstract][Full Text] [Related]
16. Concurrent TP53 mutations predict poor outcomes of EGFR-TKI treatments in Chinese patients with advanced NSCLC.
Hou H; Qin K; Liang Y; Zhang C; Liu D; Jiang H; Liu K; Zhu J; Lv H; Li T; Zhang X
Cancer Manag Res; 2019; 11():5665-5675. PubMed ID: 31417310
[No Abstract] [Full Text] [Related]
17. Genetic Profiling of Non-Small Cell Lung Cancer at Development of Resistance to First- or Second-Generation EGFR-TKIs by CAPP-Seq Analysis of Circulating Tumor DNA.
Otsubo K; Sakai K; Takeshita M; Harada D; Azuma K; Ota K; Akamatsu H; Goto K; Horiike A; Kurata T; Nakagaki N; Nosaki K; Iwama E; Nakanishi Y; Nishio K; Okamoto I
Oncologist; 2019 Aug; 24(8):1022-1026. PubMed ID: 31023862
[TBL] [Abstract][Full Text] [Related]
18. Potential Resistance Mechanisms Revealed by Targeted Sequencing from Lung Adenocarcinoma Patients with Primary Resistance to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs).
Zhong J; Li L; Wang Z; Bai H; Gai F; Duan J; Zhao J; Zhuo M; Wang Y; Wang S; Zang W; Wu M; An T; Rao G; Zhu G; Wang J
J Thorac Oncol; 2017 Dec; 12(12):1766-1778. PubMed ID: 28818608
[TBL] [Abstract][Full Text] [Related]
19. Impact of coexisting gene mutations in EGFR-mutated non-small cell lung cancer before treatment on EGFR T790M mutation status after EGFR-TKIs.
Takeda M; Sakai K; Hayashi H; Tanaka K; Haratani K; Takahama T; Kato R; Yonesaka K; Nishio K; Nakagawa K
Lung Cancer; 2020 Jan; 139():28-34. PubMed ID: 31710890
[TBL] [Abstract][Full Text] [Related]
20. Correlative analysis of gene mutation and clinical features in patients with non-small cell lung cancer.
Kuang X; Xiao J; Dai LX; Zhang LH; He BX
Transl Cancer Res; 2019 Jun; 8(3):736-751. PubMed ID: 35116812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
